Detalles de la búsqueda
1.
Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP/NF-κB/NLRP3 inflammasome circuit.
Proc Natl Acad Sci U S A
; 117(45): 28263-28274, 2020 11 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33106416
2.
SGLT2 inhibition potentiates the cardiovascular, renal, and metabolic effects of sGC stimulation in hypertensive rats with prolonged exposure to high-fat diet.
Am J Physiol Heart Circ Physiol
; 322(4): H523-H536, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35119333
3.
sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH.
Proc Natl Acad Sci U S A
; 116(22): 11057-11062, 2019 05 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-31085647
4.
Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure.
Am J Physiol Renal Physiol
; 318(1): F148-F159, 2020 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31608671
5.
Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells.
Am J Physiol Renal Physiol
; 319(4): F697-F711, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32865013
6.
Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease.
J Pharmacol Exp Ther
; 365(3): 664-675, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29643251
7.
Renal effects induced by prolonged mPGES1 inhibition.
Am J Physiol Renal Physiol
; 306(1): F68-74, 2014 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24197070
8.
pSTAT3: a target biomarker to study the pharmacology of the anti-IL-21R antibody ATR-107 in human whole blood.
J Transl Med
; 11: 65, 2013 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-23496892
9.
Leukotrienes, but not angiotensin II, are involved in the renal effects elicited by the prolonged cyclooxygenase-2 inhibition when sodium intake is low.
J Cardiovasc Pharmacol
; 61(4): 329-36, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23288201
10.
Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation.
Bioorg Med Chem Lett
; 23(4): 1114-9, 2013 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23260349
11.
Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TNBS-induced Crohn's disease model.
Dig Dis Sci
; 56(8): 2283-91, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21374065
12.
Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease.
Br J Pharmacol
; 178(17): 3463-3475, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33864386
13.
Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain.
J Pharmacol Exp Ther
; 334(1): 294-301, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20378715
14.
Biochemical, cellular, and anti-inflammatory properties of a potent, selective, orally bioavailable benzamide inhibitor of Rho kinase activity.
J Pharmacol Exp Ther
; 333(3): 707-16, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20228155
15.
Geldanamycin-induced PCNA degradation in isolated Hsp90 complex from cancer cells.
Cancer Invest
; 28(6): 635-41, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20394503
16.
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical-stage soluble guanylate cyclase stimulator in rats.
Pharmacol Res Perspect
; 8(2): e00579, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32314550
17.
Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease.
Front Pharmacol
; 11: 419, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32322204
18.
A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
Eur J Pharmacol
; 584(1): 166-74, 2008 Apr 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-18295198
19.
The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis.
Br J Pharmacol
; 175(6): 953-967, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29281143
20.
Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor.
J Pharmacol Exp Ther
; 323(3): 778-86, 2007 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17766677